Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Perampanel may reduce alpha-synuclein transmission in Parkinson's disease. A possible therapeutic target?

October 18, 2021
Dr. Michele Matarazzo speaks with Prof. Ryosuke Takahashi about the results of his recent study that shows how this anti-epileptic drug may inhibit the transmission of alpha synuclein in PD. While this was tested in animal models, future clinical trials are warranted to test the effects on PD progression. Read the article
Special thank you to:Prof. Ryosuke Takahashi
Michele Matarazzo, MD 

Neurologist and clinical researcher HM CINAC

Madrid, Spain

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice